ESR1 and cancer: Other receptors such as glucocorticoid receptor (GR), farnesoid X receptor (FXR), estrogen receptor (ER), liver X receptor (LXR) regulate the inflammatory response in several diseases such as atherosclerosis, obesity, diabetes, multiple sclerosis, cancer, and IBD [76], showing that these nuclear signaling pathways are key targets for the action of new intestinal anti-inflammatory compounds.